MedTrace Logo

Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia

NCT03487211 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-02-27

No results posted yet for this study

Summary

Duloxetine is FDA approved as pharmacological treatment for Fibromyalgia. The use of SSRIs has been endorsed by the 2013 Canadian guidelines. The data available for Escitalopram as a treatment modality for Fibromyalgia is limited, however small trials have demonstrated its efficacy. No head to head comparisons between escitalopram and duloxetine have been undertaken. We aim to conduct a single blind, randomized control trial to assess the comparative efficacy of duloxetine vs escitalopram in drug naive patients with newly diagnosed Fibromyalgia.

Conditions

  • Fibromyalgia

Interventions

DRUG

Duloxetine

Duloxetine 30mg PO once daily for 1 week followed by an increase to 60mg PO once daily

DRUG

Escitalopram

Escitalopram 10mg PO once daily for 1 week followed by an increase to 20mg PO once daily

Sponsors & Collaborators

  • Shaheed Zulfiqar Ali Bhutto Medical University

    lead OTHER

Principal Investigators

  • Mohammad A Arif, MRCP, FRCP · Shaheed Zulfiqar Ali Bhutto Medical University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-09
Primary Completion
2020-02-26
Completion
2020-02-26

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03487211 on ClinicalTrials.gov